close
References
  1. Kim RD, Greenberg DE, Ehrmantraut ME, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med. 2008;178(10):1066-1074.
  2. Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72(suppl 2):ii1-ii64.
  3. Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis. 2020;71(4):e1-e36. Erratum in: Clin Infect Dis. 2020;71(11):3023.
  4. Wagner D, van Ingen J, van der Laan R, Obradovic M; NTM-NET. Non-tuberculous mycobacterial lung disease in patients with bronchiectasis: perceived risk, severity and guideline adherence in a European physician survey. BMJ Open Respir Res. 2020;7(1):e000498.
  5. Dawrs SN, Kautz M, Chan ED, Honda JR. Mycobacterium abscessus and gastroesophageal reflux: an in vitro study. Am J Respir Crit Care Med. 2020;202(3):466-469.
  6. Thomson RM, Armstrong JG, Looke DF. Gastroesophageal reflux disease, acid suppression, and Mycobacterium avium complex pulmonary disease. Chest. 2007;131(4):1166-1172.
  7. Griffith DE, Aksamit T, Brown-Elliott BA, et al; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367-416.
  8. Basavaraj A, Segal L, Samuels J, et al. Effects of chest physical therapy in patients with non-tuberculous mycobacteria. Int J Respir Pulm Med. 2017;4(1):065.
  9. Griffith DE, Aksamit TR. Managing Mycobacterium avium complex lung disease with a little help from my friend. Chest. 2021;159(4):1372-1381.
  10. Finch S, McDonnell MJ, Abo-Leyah H, Aliberti S, Chalmers JD. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann Am Thorac Soc. 2015;12(11):1602-1611.
  11. Hill AT, Sullivan AL, Chalmers JD, et al. British Thoracic Society guideline for bronchiectasis in adults. Thorax. 2019;74(suppl 1):1-69.
  12. Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629.
  13. Ali J. A multidisciplinary approach to the management of nontuberculous mycobacterial lung disease: a clinical perspective. Expert Rev Respir Med. 2021;15(5):663-673.
  14. MYAMBUTOL (ethambutol hydrochloride). Prescribing information. Stat-Trade, Inc.; 2007.
  15. ZITHROMAX (azithromycin tablets) and (azithromycin for oral suspension). Prescribing information. Pfizer Inc.; 2013.
  16. BIAXIN Filmtab (clarithromycin tablets, USP) BIAXIN XL Filmtab (clarithromycin extended-release tablets) BIAXIN Granules (clarithromycin for oral suspension, USP). Prescribing information. Abbott Laboratories; 2011.
  17. Peloquin CA, Berning SE, Nitta AT, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis. 2004;38(11):1538-1544.
  18. ARIKAYCE (amikacin liposome inhalation suspension). Prescribing information. PARI Pharma GmbH; 2018.
  19. Vinnard C, Mezochow A, Oakland H, Klingsberg R, Hansen-Flaschen J, Hamilton K. Assessing response to therapy for nontuberculous mycobacterial lung disease: quo vadis? Front Microbiol. 2018;9:2813.
  20. Griffith DE, Adjemian J, Brown-Elliott BA, et al. Semiquantitative culture analysis during therapy for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2015;192(6):754-760.
  21. Moon SM, Jhun BW, Daley CL, Koh WJ. Unresolved issues in treatment outcome definitions for nontuberculous mycobacterial pulmonary disease. Eur Respir J. 2019;53(5):1801636.
  22. Griffith DE, Eagle G, Thomson R, et al; CONVERT Study Group. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study. Am J Respir Crit Care Med. 2018;198(12):1559-1569.
  23. Winthrop KL, Flume PA, Thomson R, et al. Amikacin liposome inhalation suspension for Mycobacterium avium complex lung disease: a 12-month open-label extension clinical trial. Ann Am Thorac Soc. 2021;18(7):1147-1157.
  24. US Food and Drug Administration. FDA approves a new antibacterial drug to treat a serious lung disease using a novel pathway to spur innovation. September 28, 2018. Accessed March 14, 2022. https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibacterial-drug-treat-serious-lung-disease-using-novel-pathway-spur-innovation